请输入关键字
请输入关键字
产品管线
开发满足患者需求的创新型抗体药物
百奥赛图致力于开发出满足患者需求的创新型抗体药物,聚焦肿瘤、自身免疫、代谢及抗感染等多个疾病领域,充分利用独特的创新药物开发优势,现已拥有包含单克隆抗体、双特异性抗体、ADC药物等在内的十多个研发管线。在强大的临床开发团队和丰富的临床资源加持下,全速推进具有巨大潜力的产品管线,加速药物临床试验进程。
Therapeutic Area
Product
Target
Partner
Molecular Format
Indication
Status
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Oncology
YH003
CD40
Monoclonal Antibody
Solid Tumors
查看更多
YH001
CTLA-4
Monoclonal Antibody
Solid Tumors
查看更多
YH002
OX40
Monoclonal Antibody
Solid Tumors
查看更多
YH004
4-1BB
Monoclonal antibody
查看更多
YH005-ADC
Claudin18.2- ADC
荣昌生物
ADC
查看更多
YH008
PD-1 x CD40
Bispecific antibody
查看更多
YH006
CTLA-4 x OX40
Bispecific antibody
查看更多
YH010
PD-L1 x IL12
Bispecific antibody
查看更多
YH011
PD-L1 x cytokine
启德医药
查看更多
YH012
HER2 x TROP2
Bispecific ADC
查看更多
YH013
EGFR x MET
Bispecific ADC
查看更多
BCG003
TNFR2
宝船生物
Monoclonal Antibody
Solid Tumors
查看更多
BCG001
B7-H3
天广实生物
Monoclonal Antibody
Solid Tumors
查看更多
BCG008
SIGLEC15
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
BCG002
CD24
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
查看更多
BCG005
CCR8
LiberoThera
Monoclonal Antibody
Solid Tumors
查看更多
BCG007
AMHR2
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
查看更多
Infectious Diseases
YH009
RSV
Monoclonal antibody
查看更多
Oncology
YH003
查看更多
Target:
CD40
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH001
查看更多
Target:
CTLA-4
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH002
查看更多
Target:
OX40
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH004
查看更多
Target:
4-1BB
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH005-ADC
查看更多
Target:
Claudin18.2- ADC
Partner:
荣昌生物
Molecular Format:
ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH008
查看更多
Target:
PD-1 x CD40
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH006
查看更多
Target:
CTLA-4 x OX40
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH010
查看更多
Target:
PD-L1 x IL12
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH011
查看更多
Target:
PD-L1 x cytokine
Partner:
启德医药
Molecular Format:
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH012
查看更多
Target:
HER2 x TROP2
Partner:
Molecular Format:
Bispecific ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH013
查看更多
Target:
EGFR x MET
Partner:
Molecular Format:
Bispecific ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG003
查看更多
Target:
TNFR2
Partner:
宝船生物
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG001
查看更多
Target:
B7-H3
Partner:
天广实生物
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG008
查看更多
Target:
SIGLEC15
Partner:
UNDISCLOSED
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG002
查看更多
Target:
CD24
Partner:
UNDISCLOSED
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG005
查看更多
Target:
CCR8
Partner:
LiberoThera
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG007
查看更多
Target:
AMHR2
Partner:
UNDISCLOSED
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
YH009
查看更多
Target:
RSV
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
百奥赛图已与全球多家药企达成抗体药物开发战略合作,点下方按钮了解合作模式。
管线项目相关合作请联系:BD-Licensing@biocytogen.com。
合作模式